SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : A US National Health Care System?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Koligman who wrote (8995)9/2/2009 9:57:13 PM
From: i-node4 Recommendations  Read Replies (2) of 42652
 
Take Erbitux, developed by ImClone Systems, which costs $10,000 a month. A study in Canada showed that as a last-ditch treatment for colorectal cancer, Erbitux lengthened lives by an average of about one and a half months compared with not treating the cancer at all.

You really have to be careful tossing around terms like "an average of about one and a half months". That could 5 years in some people and if you can identify those people, you've made a pretty big advancement.

This is just like the use of Taxol and Taxotere. On average, they may help very little but if you can isolate those people who are responsive, it can be a very effective treatment.

In June of this year, a company announced the development of a test that allows them to predict which persons will be responsive to Erbitux. For those who are, it could be a great chemo drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News